Spots Global Cancer Trial Database for Imaging Features for the Risks for Recurrence After Stereotactic Radiosurgery in Brain Metastasis

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Imaging Features for the Risks for Recurrence After Stereotactic Radiosurgery in Brain Metastasis

Official Title: Imaging Risks for Recurrence After Stereotactic Radiosurgery in Brain Metastasis (IRRAS-BM)

Study ID: NCT05868928

Conditions

Brain Metastases

Radiosurgery

Interventions

Magnetic resonance imaging (MRI)

Diffusion-weighted MRI

Arterial spin labeling (ASL)

Dynamic susceptibility contrast-MRI (DSC-MRI)

Study Description

Brief Summary: This trial uses multi-parametric magnetic resonance imaging (MRI) to develop and validate imaging risk score to predict radiation necrosis in participants with brain metastasis treated with radiation therapy. Diagnostic procedures, such as multi-parametric magnetic resonance imaging (MRI), may improve the ability to diagnose radiation necrosis early and help establish treatment strategies.

Detailed Description: PRIMARY OBJECTIVE: I. To develop an imaging risk score for recurrence after stereotactic radiosurgery (SRS) in brain metastasis using multiparametric MRI. II. To validate the imaging risk score in retrospective external validation and prospective internal validation test set. SECONDARY OBJECTIVE: I. To predict radiation necrosis using imaging risk score. OUTLINE: Participants undergo multi-parametric MRI including 3D pre- and contrast-enhanced T1 weighted image, T2 weighted image, diffusion-weighted image, dynamic susceptibility contrast MRI, and arterial spin labeling image before receiving SRS, and every 3 months after SRS.